Taysha Gene Therapies, Inc. (TSHA) is a patient-oriented, pivotal-stage gene therapy company that is passionate about eradicating severe and life-threatening monogenic diseases of the central nervous system (CNS). Headquartered in Dallas, Texas, and named after a word in the native Caddo language meaning "ally" or "friend", this biotech company strives to become the most trusted partner for those living with these devastating and often overlooked diseases.
Taysha’s culture of urgency, precision, and inclusivity is fortified by its expert team of industry veterans who bring a wide range of experiences in gene therapy and CNS drug development as well as the orphan business model upon which the company’s mission is established. The company was founded in 2018 by an experienced group of entrepreneurs including RA Session II, who is also the President, Chief Executive Officer, and Director of TSHA.
The company has rapidly expanded its portfolio to 25+ product candidates across different stages of development, establishing it as one of the most extensive gene therapy pipelines concentrated on the CNS. Its diversified portfolio includes TSHA-101, the first therapy anticipated to enter the clinic for Infantile GM2 Gangliosidosis, TSHA-118 for CLN1 disease, and TSHA-104 for SURF1-associated Leigh Syndrome, demonstrating the company’s commitment to rapidly advancing new therapeutics for patients.
TSHA’s commitment is to transform the lives of patients suffering from rare, monogenic CNS diseases. To do this, the company is focusing its resources on research, new product development, clinical development, and gene therapy manufacturing. Leveraging industry-leading proprietary technology, the team at Taysha is working on developing potentially curative treatments for patients suffering from debilitating diseases.
Taysha's commitment to science and patient health is reinforced by its exclusive partnership with leading research institutions such as UT Southwestern Medical Center. This collaboration will accelerate the process of bringing transformative therapies from bench to bedside.
Overall, Taysha Gene Therapies Inc. represents a new hope that genetic diseases of the central nervous system can be treated and potentially cured effectively. The company’s cutting-edge research, extensive gene therapy pipeline, and passionate commitment to patients poise them to make significant strides in the realm of gene therapy and rare disease treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Taysha Gene Therapies announced the completion of patient dosing in both the REVEAL pivotal and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with positive longer-term follow-up data showing consistent functional gains. The company has expanded its manufacturing partnership with Catalent and strengthened its financial position with a $230 million financing, extending its cash runway into the second half of 2028. Taysha anticipates reporting top-line data from the REVEAL trial's 6-month interim analysis and receiving FDA feedback on the BLA pathway in the first half of 2027.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus "Buy" recommendation from fourteen brokerages, with an average 12-month price target of $12.7692. Several analysts have recently increased their price targets for the stock. Despite missing its last quarterly EPS estimate, the company holds a market capitalization of $2.02 billion and analysts anticipate a -0.51 EPS for the current year.
Taysha Gene Therapies (TSHA) has seen a significant 232% return over three years, yet its current valuation, particularly its Price-to-Book ratio of 9.8x against an industry average of 2.5x, suggests it trades at a premium. The company's valuation appears to already price in expectations for its TSHA-102 gene therapy for Rett syndrome, implying a high perceived risk and reliance on successful clinical and regulatory outcomes to sustain its current premium. Investors should assess whether the future path for TSHA-102 justifies this high valuation or if any setbacks could lead to a multiple reset.
Taysha Gene Therapies, Inc. (TSHA) released its Q2 2026 earnings call summary, highlighting the completion of dosing in key trials and anticipating top-line data in H1 2027. The company's strategic focus on developmental milestones and a strong safety profile are intended to support BLA submission and market access, with current cash reserves projected to last into H2 2028.
Renaissance Technologies LLC significantly increased its stake in Taysha Gene Therapies (NASDAQ: TSHA) by 141.5% in the first quarter, acquiring an additional 242,103 shares. This brings their total holding to 413,203 shares valued at approximately $1.85 million. Despite this institutional confidence and a consensus "Buy" rating from analysts, Taysha Gene Therapies missed its quarterly EPS expectations.